Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance

Intra-Cellular Therapies (ITCI) Tops Q2 EPS by 14c, Raises FY Sales Guidance for CAPLYTA

August 3, 2023 8:09 AM EDT

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.45), $0.14 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $110.8 million versus the consensus estimate of $106.54 million.

Full year 2023 CAPLYTA net product sales guidance increased to $445 to $465 million from the previous range... More